COPD Biomarker Signatures
AssigneeLineagen, Inc.
InventorsFrancois Gervais, Viswanath Devanarayan
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of detecting differentially expressed protein expression indicative of COPD in a test sample. The detection of circulating levels of proteins within an identified COPD biomarker signature can aid in COPD diagnosis and disease monitoring, as well as in the prediction of responses to therapeutics. Evaluation of the biomarker signatures disclosed, or a subset of biomarkers thereof, provides a level of discrimination not found with individual markers.
Claims12
1-20. (canceled)
A kit, comprising first antibodies or first antibody fragments for detecting at least three protein markers, or corresponding peptides thereof, selected from each of two or more multi-analyte panels selected from the group consisting of:
- multi-analyte panel (a) apolipoprotein H, CD40, haptoglobin, interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor receptor II (TNF-RII);
- multi-analyte panel (b) apolipoprotein CIII, CD40, granulocyte-macrophage colony stimulating factor (GM-CSF), haptoglobin, immunoglobulin A (IgA), macrophage inflammatory protein 1alpha (MIP-1α), tissue factor and tumor necrosis factor-alpha (TNF-α);
- and
- multi-analyte panel (c) alpha-1 antitrypsin, C-reactive protein (CRP), fibrinogen, granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-4 (IL-4), macrophage-derived chemokine (MDC), tissue factor, tumor necrosis factor receptor II (TNFRII) and soluble vascular cell adhesion molecule 1 (sVCAM-1);
- wherein said first antibodies or first antibody fragments are bound to a solid phase or labeled with a detectable label.
A composition comprising first antibodies or first antibody fragments for detecting at least three protein markers, or peptides thereof, selected from each of two or more multi-analyte panels selected from the group consisting of:
- multi-analyte panel (a) apolipoprotein H, CD40, haptoglobin, interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor receptor II (TNF-RII);
- multi-analyte panel (b) apolipoprotein CIII, CD40, granulocyte-macrophage colony stimulating factor (GM-CSF), haptoglobin, immunoglobulin A (IgA), macrophage inflammatory protein 1alpha (MIP-1α), tissue factor and tumor necrosis factor-alpha (TNF-α);
- and
- multi-analyte panel (c) alpha-1 antitrypsin, C-reactive protein (CRP), fibrinogen, granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-4 (IL-4), macrophage-derived chemokine (MDC), tissue factor, tumor necrosis factor receptor II (TNFRII) and soluble vascular cell adhesion molecule 1 (sVCAM-1);
- wherein said first antibodies or first antibody fragments are bound to a solid phase, and wherein the composition does not comprise antibodies against at least one of the proteins in the multi-analyte panels.
Dependencies are inferred from the claim text.